{"id":159549,"date":"2025-11-21T03:06:19","date_gmt":"2025-11-21T03:06:19","guid":{"rendered":"https:\/\/www.europesays.com\/pt\/159549\/"},"modified":"2025-11-21T03:06:19","modified_gmt":"2025-11-21T03:06:19","slug":"acordo-multimilionario-para-novo-medicamento-contra-parkinson","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/pt\/159549\/","title":{"rendered":"Acordo multimilion\u00e1rio para novo medicamento contra Parkinson"},"content":{"rendered":"<p class=\"wp-caption-text top\"><a href=\"https:\/\/www.flickr.com\/photos\/yanivg\/4365779668\/sizes\/l\" rel=\"nofollow external noopener noreferrer\" data-wpel-link=\"external\" target=\"_blank\" class=\"ext-link\">yanivg \/ Flickr <\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"size-kopa-image-size-3 wp-image-181095\" src=\"https:\/\/www.europesays.com\/pt\/wp-content\/uploads\/2025\/11\/ae9b6b50c4425356a3d3614338f055c4-783x450.jpg\" alt=\"\" width=\"700\" height=\"402\"  \/><\/p>\n<p><strong>Merck fechou acordo com Valo Health para desenvolver um novo medicamento; v\u00e3o ter ajuda da intelig\u00eancia artificial.<\/strong><\/p>\n<p>Continua a corrida da luta contra a <strong>Parkinson,<\/strong> sobretudo no contexto farmac\u00eautico.<\/p>\n<p>Nesta quinta-feira foi anunciado um acordo multimilion\u00e1rio entre a <strong>Merck<\/strong> e a <strong>Valo Health.<\/strong><\/p>\n<p>Os alem\u00e3es da Merck s\u00e3o uma empresa ligada \u00e0s ind\u00fastrias qu\u00edmica, farmac\u00eautica e de ci\u00eancias biol\u00f3gicas; a Valo Health, dos EUA, \u00e9 uma empresa tecnol\u00f3gica focada no desenvolvimento de medicamentos utilizando dados em larga escala e computa\u00e7\u00e3o baseada em intelig\u00eancia artificial.<\/p>\n<p>Ou seja, a Merck faz um <strong>investimento em for\u00e7a<\/strong> e conta com o aux\u00edlio da <strong>intelig\u00eancia artificial.<\/strong><\/p>\n<p>Ao todo s\u00e3o 3 mil milh\u00f5es de d\u00f3lares, ou <strong>2,6 mil milh\u00f5es de euros<\/strong>, que ser\u00e3o pagos por etapas, anunciou a Valo Health.<\/p>\n<p>E ainda haver\u00e1 valores extra, entre taxas de licenciamento e financiamento para investiga\u00e7\u00e3o, avan\u00e7a o <a href=\"https:\/\/www.handelsblatt.com\/unternehmen\/industrie\/pharmabranche-merck-schliesst-milliardendeal-fuer-neues-parkinson-medikament\/100176716.html\" data-wpel-link=\"external\" target=\"_blank\" rel=\"nofollow external noopener noreferrer\" class=\"ext-link\">Handelsblatt<\/a>.<\/p>\n<p>Al\u00e9m da sua plataforma de pesquisa baseada em intelig\u00eancia artificial, a Valo Health tem um <strong>banco de dados com mais de 17 milh\u00f5es de registos<\/strong> de pacientes (an\u00f3nimos).<\/p>\n<p>Segundo a empresa, assim consegue otimizar o desenvolvimento de medicamentos, \u201cpara que possamos avan\u00e7ar mais rapidamente com os candidatos mais promissores\u201d.<\/p>\n<p>A doen\u00e7a de Parkinson afeta cerca de 10 milh\u00f5es de pessoas em todo o planeta; em Portugal, estima-se que haja cerca de 20 mil doentes de Parkinson.<\/p>\n<p>Os sintomas mais comuns incluem rigidez muscular, movimentos lentos e tremores incontrol\u00e1veis.<\/p>\n<p>    <a href=\"https:\/\/zap.aeiou.pt\/subscrever-newsletter\" data-wpel-link=\"internal\" rel=\"nofollow noopener\" target=\"_blank\">&#13;<br \/>\n        <img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-575475\" src=\"https:\/\/www.europesays.com\/pt\/wp-content\/uploads\/2025\/11\/2d51fe4a0ba54894421ead1809309ed9-1-450x140.jpg\" alt=\"Subscreva a Newsletter ZAP\" width=\"450\" height=\"140\"\/>&#13;<br \/>\n    <\/a><\/p>\n<p>                <a href=\"https:\/\/whatsapp.com\/channel\/0029VaIC4EE2f3EJZPPSbR34\" data-wpel-link=\"external\" target=\"_blank\" rel=\"nofollow external noopener noreferrer\" class=\"ext-link\">&#13;<br \/>\n                    <img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-575475\" src=\"https:\/\/www.europesays.com\/pt\/wp-content\/uploads\/2025\/11\/c68c559d956d4ca20f435ed74a6e71e6.png\" alt=\"Siga-nos no WhatsApp\" width=\"175\" height=\"64\"\/>&#13;<br \/>\n                <\/a><\/p>\n<p>                <a href=\"https:\/\/news.google.com\/publications\/CAAiEHRwZondIV71PDjWNoqMduEqFAgKIhB0cGaJ3SFe9Tw41jaKjHbh?hl=en-US&amp;gl=US&amp;ceid=US%3Aen\" data-wpel-link=\"external\" target=\"_blank\" rel=\"nofollow external noopener noreferrer\" class=\"ext-link\">&#13;<br \/>\n                    <img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-575475\" src=\"https:\/\/www.europesays.com\/pt\/wp-content\/uploads\/2025\/11\/5123dd8b087b644fdb8f8603acd1bad4.png\" alt=\"Siga-nos no Google News\" width=\"176\" height=\"64\"\/>&#13;<br \/>\n                <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"yanivg \/ Flickr Merck fechou acordo com Valo Health para desenvolver um novo medicamento; v\u00e3o ter ajuda da&hellip;\n","protected":false},"author":2,"featured_media":159550,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[1305,90,413,116,2172,933,1208,1492,32,33,117,110],"class_list":{"0":"post-159549","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-saude","8":"tag-alemanha","9":"tag-empresas","10":"tag-eua","11":"tag-health","12":"tag-inovacao","13":"tag-inteligencia-artificial","14":"tag-medicina","15":"tag-parkinson","16":"tag-portugal","17":"tag-pt","18":"tag-saude","19":"tag-tecnologia"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@pt\/115585482012382692","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts\/159549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/comments?post=159549"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts\/159549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/media\/159550"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/media?parent=159549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/categories?post=159549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/tags?post=159549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}